9989 — Shenzhen Hepalink Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- HK$4.92bn
- HK$7.13bn
- CNY5.45bn
- 29
- 73
- 57
- 54
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | CAS | CAS | CAS | CAS | CAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4,625 | 5,332 | 6,365 | 7,159 | 5,446 |
Cost of Revenue | |||||
Gross Profit | 1,677 | 2,032 | 1,998 | 2,296 | 945 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,310 | 4,002 | 6,139 | 6,331 | 6,307 |
Operating Profit | 1,315 | 1,330 | 226 | 828 | -862 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,315 | 1,328 | 222 | 830 | -928 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,044 | 1,022 | 233 | 715 | -802 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1,059 | 1,024 | 241 | 727 | -783 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,059 | 1,024 | 241 | 727 | -783 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.848 | 0.698 | 0.266 | 0.485 | -0.497 |
Dividends per Share |